A murine BCR-ABL+Arf−/− B-ALL (mB-ALL) model was used to test whether treatment with αGAL-9 antibody could be used as a therapy to treat obese mice with B-ALL. Here, CDKN2A is linked to acute lymphoblastic leukemia.